Sharma Mahima, Dixit Aparna
Gene Regulation Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi, 110067, India.
Appl Microbiol Biotechnol. 2015 Aug;99(15):6277-91. doi: 10.1007/s00253-015-6398-3. Epub 2015 Jan 31.
Aeromonas hydrophila, a ubiquitous and virulent bacterial pathogen, affects a variety of fishes, including Labeo rohita. Existing treatment strategies comprise antibiotic therapies and attenuated bacterial strain-based vaccines. No functional subunit vaccine has been available until now. Given their key role in determining pathogenicity, outer membrane proteins have been successfully explored as potential vaccine candidates. We have devised a direct strategy for eliminating non-specific responses by selectively aiming the immune response against specific immunodominant epitopes of the outer membrane protein F (OmpF) of A. hydrophila (AhOmpF). Five putative epitopes of AhOmpF predicted in silico were genetically conjugated with heat labile enterotoxin chain B of E. coli (LTB). Recombinant fusion proteins expressed in E. coli were purified from solubilized inclusion bodies and refolded. The fusion protein retained GM1 ganglioside receptor binding activity of LTB, indicating proper folding. Four of the five fusion proteins were found to be highly immunogenic. Of the four proteins, antisera against the fusion protein (anti-rEpiF1) harboring 66-80 amino acid residues of the OmpF gave maximum cross-reactivity with the targeted rOmpF in enzyme-linked immunosorbent assay (ELISA) and was able to recognize both fusion partners-rOmpF and rLTB-in Western blot. Antibody isotyping of the antisera and cytokine array analysis of the culture supernatants of splenocytes from sensitized mice manifested a mixed Th1/Th2 immune response with a bias toward Th2. Anti-rEpiF1 antibodies were able to bind to the cell membrane of live A. hydrophila cells and agglutinate them. Our results thus suggest that the OmpF epitope (66-80) in fusion with a carrier protein is a promising vaccine candidate against A. hydrophila.
嗜水气单胞菌是一种普遍存在且具有致病性的细菌病原体,可感染包括印度野鲮在内的多种鱼类。现有的治疗策略包括抗生素疗法和基于减毒菌株的疫苗。到目前为止,尚无功能性亚单位疫苗。鉴于外膜蛋白在决定致病性方面的关键作用,它们已被成功探索作为潜在的疫苗候选物。我们设计了一种直接策略,通过选择性地针对嗜水气单胞菌外膜蛋白F(AhOmpF)的特定免疫显性表位来消除非特异性反应。在计算机上预测的AhOmpF的五个假定表位与大肠杆菌热不稳定肠毒素B链(LTB)进行基因偶联。在大肠杆菌中表达的重组融合蛋白从溶解的包涵体中纯化并复性。融合蛋白保留了LTB的GM1神经节苷脂受体结合活性,表明折叠正确。发现五个融合蛋白中的四个具有高度免疫原性。在这四种蛋白中,针对含有OmpF 66 - 80个氨基酸残基的融合蛋白(抗rEpiF1)的抗血清在酶联免疫吸附测定(ELISA)中与靶向的rOmpF具有最大交叉反应性,并且能够在蛋白质印迹中识别两个融合伙伴 - rOmpF和rLTB。抗血清的抗体分型和致敏小鼠脾细胞培养上清液的细胞因子阵列分析显示出混合的Th1/Th2免疫反应,且偏向Th2。抗rEpiF1抗体能够结合活的嗜水气单胞菌细胞并使其凝集。因此,我们的结果表明,与载体蛋白融合的OmpF表位(66 - 80)是一种有前景的抗嗜水气单胞菌疫苗候选物。